Merck & Co., Inc. MRK
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 67.38B | 66.57B | 65.77B | 65.01B | 64.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.38B | 66.57B | 65.77B | 65.01B | 64.24B |
| Cost of Revenue | 16.71B | 16.04B | 15.31B | 14.82B | 14.23B |
| Gross Profit | 50.67B | 50.53B | 50.46B | 50.20B | 50.01B |
| SG&A Expenses | 10.84B | 10.56B | 10.28B | 10.11B | 10.07B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.39B | 47.90B | 41.13B | 40.44B | 36.95B |
| Operating Income | 17.99B | 18.67B | 24.63B | 24.57B | 27.29B |
| Income Before Tax | 4.76B | 5.95B | 11.63B | 21.07B | 21.82B |
| Income Tax Expenses | 2.31B | 2.78B | 2.70B | 2.81B | 2.77B |
| Earnings from Continuing Operations | 2.45K | 3.17K | 8.93K | 18.26K | 19.04K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.00M | 4.00M | 1.00M | -8.00M | -10.00M |
| Net Income | 2.45B | 3.17B | 8.94B | 18.25B | 19.03B |
| EBIT | 17.99B | 18.67B | 24.63B | 24.57B | 27.29B |
| EBITDA | 23.79B | 24.06B | 29.62B | 29.21B | 31.62B |
| EPS Basic | 0.99 | 1.25 | 3.56 | 7.29 | 7.57 |
| Normalized Basic EPS | 4.08 | 4.30 | 5.84 | 5.85 | 6.52 |
| EPS Diluted | 0.97 | 1.25 | 3.55 | 7.28 | 7.56 |
| Normalized Diluted EPS | 4.07 | 4.29 | 5.83 | 5.84 | 6.51 |
| Average Basic Shares Outstanding | 9.90B | 9.93B | 9.97B | 10.02B | 10.07B |
| Average Diluted Shares Outstanding | 9.91B | 9.93B | 9.97B | 10.03B | 10.08B |
| Dividend Per Share | 3.36 | 3.32 | 3.28 | 3.24 | 3.20 |
| Payout Ratio | 341.05% | 261.52% | 92.12% | 44.79% | 42.60% |